NCT05830136 Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy
| NCT ID | NCT05830136 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | Hepatic Ischemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-02-01 |
| Primary Completion | 2026-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-02-01 with a primary completion date of 2026-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Compared the effects of Sodium bicarbonate Ringer's solution and lactate Ringer's solution on the internal environment and hemodynamics of patients during laparoscopic liver resection, to observe the application prospect of sodium bicarbonate Ringer's solution in Laparoscopic hepatectomy.
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years old, 2. patients who plan to undergoing laparoscopic hepatectomy ; 3. Willing to sign informed consent. Exclusion Criteria: 1. age \<18 years 2. pregnancy 3. active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, history of congestive heart failure) 4. history of significant cerebrovascular disease 5. restrictive or obstructive pulmonary disease 6. uncontrolled hypertension 7. renal dysfunction (glomerular filtration rate \<60 mL/min), 8. evidence of hepatic metabolic disorder (bilirubin \>35 mmol/L) 9. presence of active infection
Contact & Investigator
Shijiang Liu
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT05830136 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatic Ischemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05830136 currently recruiting?
Yes, NCT05830136 is actively recruiting participants. Contact the research team at liushijiang@jsph.org.cn for enrollment information.
Where is the NCT05830136 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT05830136 clinical trial?
NCT05830136 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Shijiang Liu at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 100 participants.